Similar articles for PMID: 33795249

Year	Number of Results
2012	1
2015	1
2016	6
2017	9
2018	14
2019	15
2020	12
2021	7
2024	0

1

[No authors listed] [No authors listed] Cleve Clin J Med. 2021 Apr 1;88(4):205. Cleve Clin J Med. 2021. PMID: 33795249 Free article. No abstract available.

2

SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review.

Raj H, Durgia H, Palui R, Kamalanathan S, Selvarajan S, Kar SS, Sahoo J. Raj H, et al. World J Diabetes. 2019 Feb 15;10(2):114-132. doi: 10.4239/wjd.v10.i2.114. World J Diabetes. 2019. PMID: 30788048 Free PMC article.

3

Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.

Handelsman Y. Handelsman Y. Adv Ther. 2019 Oct;36(10):2567-2586. doi: 10.1007/s12325-019-01054-w. Epub 2019 Aug 23. Adv Ther. 2019. PMID: 31444707 Free PMC article. Review.

4

Sodium-glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes.

Schwartz SS, Ahmed I. Schwartz SS, et al. Curr Med Res Opin. 2016 May;32(5):907-19. doi: 10.1185/03007995.2016.1151774. Epub 2016 Feb 26. Curr Med Res Opin. 2016. PMID: 26854518 Review.

5

Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis.

Yamada T, Wakabayashi M, Bhalla A, Chopra N, Miyashita H, Mikami T, Ueyama H, Fujisaki T, Saigusa Y, Yamaji T, Azushima K, Urate S, Suzuki T, Abe E, Wakui H, Tamura K. Yamada T, et al. Cardiovasc Diabetol. 2021 Jan 7;20(1):14. doi: 10.1186/s12933-020-01197-z. Cardiovasc Diabetol. 2021. PMID: 33413348 Free PMC article.

6

Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes.

Mende CW. Mende CW. Curr Med Res Opin. 2017 Mar;33(3):541-551. doi: 10.1080/03007995.2016.1271779. Epub 2017 Jan 4. Curr Med Res Opin. 2017. PMID: 27977314 Review.

7

Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysis.

Mishriky BM, Tanenberg RJ, Sewell KA, Cummings DM. Mishriky BM, et al. Diabetes Metab. 2018 Mar;44(2):112-120. doi: 10.1016/j.diabet.2018.01.017. Epub 2018 Feb 7. Diabetes Metab. 2018. PMID: 29477373 Review.

8

SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature.

Imprialos K, Faselis C, Boutari C, Stavropoulos K, Athyros V, Karagiannis A, Doumas M. Imprialos K, et al. Curr Pharm Des. 2017;23(10):1510-1521. doi: 10.2174/1381612823666170124123927. Curr Pharm Des. 2017. PMID: 28120716 Review.

9

[Outcome studies on SGLT-2 inhibitors].

Seufert J, Laubner K. Seufert J, et al. Internist (Berl). 2019 Sep;60(9):903-911. doi: 10.1007/s00108-019-0656-x. Internist (Berl). 2019. PMID: 31375850 Review. German.

10

Effects of sodium-glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: A meta-analysis of randomized controlled trials.

Lu J, Tang L, Meng H, Zhao J, Liang Y. Lu J, et al. Diabetes Metab Res Rev. 2019 Oct;35(7):e3169. doi: 10.1002/dmrr.3169. Epub 2019 May 9. Diabetes Metab Res Rev. 2019. PMID: 30974510 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

58 results

Results by year